Dr. Jeffrey S. Miller to Present on Progress of GTB-3550 TriKE™ Phase I Trial Accompanying GT Biopharma’s Company Presentation at Raymond James Human Health Innovation Conference

BEVERLY HILLS, Calif.: BEVERLY HILLS, Calif., June 21, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that Dr....

Click to view original post